How Long Does Aristada Stay in Your System After the Last Shot?
Aristada (aripiprazole lauroxil), a long-acting injectable antipsychotic, converts to active aripiprazole in the body. Its elimination depends on the dose (441 mg, 882 mg, or 1320 mg every 4-6 weeks) and individual factors like metabolism and liver function. After the last injection, detectable levels persist for months due to its depot formulation, but therapeutic effects and plasma concentrations decline gradually.
Plasma concentrations of aripiprazole typically remain above 50% of peak for 3-4 months post-injection, with half-lives ranging from 29-46 days for the prodrug and 75-94 days for active aripiprazole.[1] Full clearance—below detectable limits (<0.1 ng/mL)—takes 4-6 months or longer, based on pharmacokinetic studies in patients with schizophrenia.
| Dose | Time to Steady State | Approximate Time for Half Peak Levels After Last Dose |
|------|----------------------|-----------------------------------------------------|
| 441 mg (monthly) | 4 months | 2-3 months |
| 882 mg (monthly) | 5 months | 3-4 months |
| 1320 mg (6 weeks) | 4-5 months | 3-4 months |
Data from manufacturer trials; actual duration varies.[1]
What Affects How Long It Stays Active?
Age, smoking (induces faster metabolism), CYP2D6 poor metabolizers (slower clearance), and concomitant drugs like carbamazepine (speeds elimination) or quinidine (slows it) alter pharmacokinetics. In elderly patients, half-life extends up to 120 days.[1] No routine blood tests measure "stay time," but clinicians monitor symptoms for relapse risk during taper.
When Do Effects Wear Off for Most Patients?
Therapeutic antipsychotic effects last 4-8 weeks per dose, but residual benefits from prior steady-state dosing can persist 1-3 months after stopping. Relapse risk rises after 2-3 months without re-dosing, per long-term studies.[2] Patients often switch to oral aripiprazole during this window to bridge clearance.
Can It Be Detected in Drug Tests After Stopping?
Urine tests for aripiprazole are uncommon outside clinical settings. If tested, it may show for 1-3 months post-last shot via LC-MS/MS, similar to plasma detection windows. Standard employment panels don't screen for it.[3]
Risks of Abrupt Stop and Switching
Sudden discontinuation risks withdrawal (insomnia, nausea, psychosis rebound) within 1-4 weeks. FDA recommends gradual oral overlap. For emergencies, activated charcoal or hemodialysis has limited effect due to protein binding.[1]
[1]: Aristada Prescribing Information (Alkermes)
[2]: Journal of Clinical Psychiatry: Aripiprazole Lauroxil Pharmacokinetics
[3]: FDA Label and Clinical Pharmacology Review